1. NLRP3 Inflammasome-Mediated Inflammation in Acute Pancreatitis.
- Author
-
Ferrero-Andrés A, Panisello-Roselló A, Roselló-Catafau J, and Folch-Puy E
- Subjects
- Animals, Gene Expression Regulation, Glyburide therapeutic use, Humans, Indomethacin therapeutic use, Inflammasomes immunology, Inflammasomes metabolism, Inflammation, Interleukin-18 genetics, Interleukin-18 immunology, Interleukin-1beta genetics, Interleukin-1beta immunology, Myeloid Differentiation Factor 88 genetics, Myeloid Differentiation Factor 88 immunology, NLR Family, Pyrin Domain-Containing 3 Protein antagonists & inhibitors, NLR Family, Pyrin Domain-Containing 3 Protein immunology, Pancreas drug effects, Pancreas pathology, Pancreatitis drug therapy, Pancreatitis immunology, Pancreatitis pathology, Signal Transduction, Toll-Like Receptor 3 genetics, Toll-Like Receptor 3 immunology, Withanolides therapeutic use, Anti-Inflammatory Agents therapeutic use, Inflammasomes drug effects, NLR Family, Pyrin Domain-Containing 3 Protein genetics, Pancreas immunology, Pancreatitis genetics
- Abstract
The discovery of inflammasomes has enriched our knowledge in the pathogenesis of multiple inflammatory diseases. The NLR pyrin domain-containing protein 3 (NLRP3) has emerged as the most versatile and well-characterized inflammasome, consisting of an intracellular multi-protein complex that acts as a central driver of inflammation. Its activation depends on a tightly regulated two-step process, which includes a wide variety of unrelated stimuli. It is therefore not surprising that the specific regulatory mechanisms of NLRP3 inflammasome activation remain unclear. Inflammasome-mediated inflammation has become increasingly important in acute pancreatitis, an inflammatory disorder of the pancreas that is one of the fatal diseases of the gastrointestinal tract. This review presents an update on the progress of research into the contribution of the NLRP3 inflammasome to acute pancreatic injury, examining the mechanisms of NLRP3 activation by multiple signaling events, the downstream interleukin 1 family of cytokines involved and the current state of the literature on NLRP3 inflammasome-specific inhibitors.
- Published
- 2020
- Full Text
- View/download PDF